Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy

L Lorenzo Maso (Perlmutter Cancer Center, New York University Langone Health) S Sarah A. Mosure S Sergio A. Rodriguez-Aponte A Angelina Pizzo D Diamond N. Mensah M Matthew Southard S Samantha Sze T Tanvir Ahmed B Brian Vash T Takamitsu Hattori E Epsa Rajak (Perlmutter Cancer Center, New York University Langone Health) A Akiko Koide B Benjamin G. Neel (Perlmutter Cancer Center, New York University Langone Health) S Shohei Koide W Weifeng Liu S Sean T. Toenjes (Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine) P Paul Da Silva Jardine R Rajesh Chopra C Christoph Rader L Lauren E. Stopfer

Article Details

Volume / Issue Vol. 16, Issue 1
Published December 17, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (20)

L

Lorenzo Maso

Perlmutter Cancer Center, New York University Langone Health

S

Sarah A. Mosure

S

Sergio A. Rodriguez-Aponte

A

Angelina Pizzo

D

Diamond N. Mensah

M

Matthew Southard

S

Samantha Sze

T

Tanvir Ahmed

B

Brian Vash

T

Takamitsu Hattori

E

Epsa Rajak

Perlmutter Cancer Center, New York University Langone Health

A

Akiko Koide

B

Benjamin G. Neel

Perlmutter Cancer Center, New York University Langone Health

S

Shohei Koide

W

Weifeng Liu

S

Sean T. Toenjes

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

P

Paul Da Silva Jardine

R

Rajesh Chopra

C

Christoph Rader

L

Lauren E. Stopfer